ArticleIndian journal of orthopaedics2025
Circulating miR-19b in Serum Exosomes: A Novel Biomarker for Estrogen-Associated Osteoporosis.
Article in Indian journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoporosis, a significant health concern among postmenopausal women, is influenced by estrogen deficiency, which affects bone metabolism. Current diagnostic methods, such as dual-energy X-ray absorptiometry (DXA), have limitations in sensitivity, necessitating the identification of novel biomarkers for early diagnosis. This study investigates the role of circulating exosomal miR-19b as a potential biomarker for estrogen-associated osteoporosis. Methods: We analyzed the expression of miR-19b in MC3T3-E1 preosteoblast cells treated with 10 pM estradiol and assessed its antagonistic effects using 10 nM anastrozole. Serum exosomes were isolated from premenopausal (PR-M) and postmenopausal (PT-M) women using microfluidics-based extracellular vesicle (EV) isolation. Exosomal miR-19b expression was quantified using qRT-PCR, and its correlation with age, estrogen levels, and osteoporosis risk was evaluated. Characterization of exosomes was performed using transmission electron microscopy (TEM) and tunable resistive pulse sensing (TRPS), while protein markers CD9, CD63, and β-actin were confirmed through Western blot analysis. Results: Our findings demonstrate that estrogen downregulates exosomal miR-19b expression, with a significant difference observed between the PR-M and PT-M groups. Receiver operating characteristic (ROC) analysis revealed that miR-19b effectively differentiates between these groups, with an area under the curve (AUC) of 0.9911. Pearson correlation analysis further confirmed the strong association between miR-19b expression, estrogen levels, and age. Additionally, miR-19b inhibition was found to regulate IGF-1 expression, influencing bone cell differentiation and osteoporosis progression. Conclusion: This study establishes exosomal miR-19b as a novel biomarker for estrogen-related osteoporosis, providing a foundation for early diagnosis and therapeutic targeting. Our findings highlight the potential of exosomal miRNAs in advancing precision medicine for osteoporosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.